Evidence map›Paper›PMID 40301197›Full record

ArticleEJNMMI research2025

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer.

Chi-Chang Weng, Chao-Chih Chiang, Yi-Hsiu Chung, Yi-Pei Ho, Yu-Chuan Chang, Ing-Tsung Hsiao, Robert H Mach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chi-Chang WengDepartment of Medical Imaging and Radiological Sciences, College of Medicine & Healthy Aging Center, Chang Gung University, Taoyuan, Taiwan. ccweng@mail.cgu.edu.tw.ORCID http://orcid.org/0000-0002-2989-3303
Chao-Chih ChiangDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan, Taiwan.
Yi-Hsiu ChungDepartment of Medical Research and Development, Research Division, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan.
Yi-Pei HoDepartment of Medical Imaging and Radiological Sciences, College of Medicine & Healthy Aging Center, Chang Gung University, Taoyuan, Taiwan.
Yu-Chuan ChangDepartment of Medical Imaging and Radiological Sciences, College of Medicine & Healthy Aging Center, Chang Gung University, Taoyuan, Taiwan.
Ing-Tsung HsiaoDepartment of Medical Imaging and Radiological Sciences, College of Medicine & Healthy Aging Center, Chang Gung University, Taoyuan, Taiwan.
Robert H MachDivision of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Funding

Chang Gung Memorial Hospital CMRPD1M0243Chang Gung Memorial Hospital CMRPG3N0461Chang Gung Memorial Hospital CMRPG3N0462National Atomic Research Institute NSC-112-80-01-03-01-02National Science and Technology Council MOST 108-2314-B-182-063-
6 · The paper itself

Abstract

backgroundSeveral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors were recently approved by the US Food and Drug Administration for use in cancer treatment. To facilitate the discovery of novel PARP-targeting ligands, a radioiodinated ligand, I-125-KX1, was developed and validated for its specificity to PARP-1; however, its preparation procedure is time-consuming. The present study employed a solid-phase extraction (SPE) method in the radiolabeling procedure of I-123/125-KX1 and evaluated its binding specificity by using receptor binding assays, autoradiography, and in vivo single photon emission computed tomography (SPECT) imaging technique.

resultsThrough the incorporation of the SPE purification method as the final step in the radioiodination procedure, the resultant product I-123/125-KX1 exhibited high radiochemical purity (> 99%) and an acceptable radiochemical yield (58.6% for I-123-KX1, 73.3% for I-125-KX1). The binding characteristics of this radiotracer were validated through saturation binding assays conducted on MDA-MB-231 and MCF-7 cells. The K

conclusionsThis suggests that the I-123/125-KX1 prepared using the SPE method showed some comparable properties to those from the traditional method, indicating its potential suitability for future radioligand preparation in PARP studies. However, further characterization studies may be needed to confirm its efficacy.

Indexed as

Breast cancerI-123/125-KX1In vitro autoradiographyIn vivo SPECT imagingPARPSaturation binding assaySPE

Identifiers

PMID40301197
PMCPMC12040802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.